- Home
- KOD vs TSHA Comparison
KOD vs TSHA Comparison
Compare KOD & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | TSHA |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KOD | TSHA |
|---|---|---|
| Price | $25.28 | $4.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $28.29 | $10.56 |
| AVG Volume (30 Days) | 656.3K | ★ 2.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.60 | ★ 62.50 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,333,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.92 | $1.13 |
| 52 Week High | $31.18 | $6.02 |
Technical Indicators
Market Signals| Indicator | KOD | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 53.93 | 50.05 |
| Support Level | $21.51 | $4.45 |
| Resistance Level | $27.99 | $4.83 |
| Average True Range (ATR) | 2.02 | 0.24 |
| MACD | 0.33 | 0.04 |
| Stochastic Oscillator | 66.67 | 72.73 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.